0	4	CD30	CD30	NNP
5	7	is	be	VBZ
8	9	a	a	DT
10	24	CD40-inducible	cd40-inducible	JJ
25	33	molecule	molecule	NN
34	38	that	that	WDT
39	49	negatively	negatively	RB
50	59	regulates	regulate	VBZ
60	73	CD40-mediated	cd40-mediated	JJ
74	88	immunoglobulin	immunoglobulin	NN
89	94	class	class	NN
95	104	switching	switching	NN
105	107	in	in	IN
108	128	non-antigen-selected	non-antigen-selected	JJ
129	134	human	human	JJ
135	136	B	b	NN
137	142	cells	cell	NNS
142	143	.	.	.

145	147	We	we	PRP
148	152	used	use	VBD
153	156	our	our	PRP$
157	167	monoclonal	monoclonal	JJ
168	173	model	model	NN
174	176	of	of	IN
177	185	germinal	germinal	JJ
186	192	center	center	NN
193	203	maturation	maturation	NN
203	204	,	,	,
205	210	CL-01	CL-01	NNP
211	212	B	B	NNP
213	218	cells	cell	NNS
218	219	,	,	,
220	222	to	to	TO
223	234	investigate	investigate	VB
235	238	the	the	DT
239	243	role	role	NN
244	246	of	of	IN
247	251	CD30	cd30	NN
252	254	in	in	IN
255	260	human	human	JJ
261	262	B	B	NNP
263	267	cell	cell	NN
268	283	differentiation	differentiation	NN
283	284	.	.	.

285	290	CL-01	cl-01	NN
291	296	cells	cell	NNS
297	300	are	be	VBP
301	305	IgM+	igm+	JJ
306	310	IgD+	igd+	JJ
311	316	CD30+	cd30+	JJ
317	320	and	and	CC
321	327	switch	switch	NN
328	330	to	to	TO
331	334	IgG	IgG	NNP
334	335	,	,	,
336	339	IgA	IgA	NNP
339	340	,	,	,
341	344	and	and	CC
345	348	IgE	ige	NN
349	353	when	when	WRB
354	361	exposed	expose	VBN
362	364	to	to	TO
365	370	CD40L	CD40L	NNP
371	374	and	and	CC
375	379	IL-4	il-4	NN
379	380	.	.	.

381	390	Switching	switching	NN
391	393	is	be	VBZ
394	402	hampered	hamper	VBN
403	405	by	by	IN
406	410	CD30	cd30	NN
411	423	coengagement	coengagement	NN
423	424	,	,	,
425	433	possibly	possibly	RB
434	441	through	through	IN
442	454	interference	interference	NN
455	459	with	with	IN
460	463	the	the	DT
464	477	CD40-mediated	cd40-mediated	JJ
478	497	NF-kappaB-dependent	nf-kappab-dependent	JJ
498	513	transcriptional	transcriptional	JJ
514	524	activation	activation	NN
525	527	of	of	IN
528	538	downstream	downstream	JJ
539	543	C(H)	c(h)	NN
544	549	genes	gene	NNS
549	550	.	.	.

551	554	The	the	DT
555	568	physiological	physiological	JJ
569	578	relevance	relevance	NN
579	581	of	of	IN
582	586	this	this	DT
587	597	phenomenon	phenomenon	NN
598	600	is	be	VBZ
601	611	emphasized	emphasize	VBN
612	614	by	by	IN
615	622	similar	similar	JJ
623	636	CD30-mediated	cd30-mediated	JJ
637	644	effects	effect	NNS
645	647	in	in	IN
648	653	naive	naive	JJ
654	655	B	B	NNP
656	661	cells	cell	NNS
661	662	.	.	.

663	673	Expression	expression	NN
674	676	of	of	IN
677	681	CD30	cd30	NN
682	684	by	by	IN
685	690	these	these	DT
691	696	cells	cell	NNS
697	699	is	be	VBZ
700	707	induced	induce	VBN
708	710	by	by	IN
711	716	CD40L	CD40L	NNP
717	720	but	but	CC
721	723	is	be	VBZ
724	733	inhibited	inhibit	VBN
734	736	by	by	IN
737	738	B	B	NNP
739	743	cell	cell	NN
744	752	receptor	receptor	NN
753	765	coengagement	coengagement	NN
766	772	and/or	and/or	CC
773	781	exposure	exposure	NN
782	784	to	to	TO
785	789	IL-6	il-6	NN
790	793	and	and	CC
794	799	IL-12	il-12	NN
799	800	.	.	.

801	804	Our	our	PRP$
805	809	data	datum	NNS
810	817	suggest	suggest	VBP
818	822	that	that	IN
823	827	CD30	cd30	NN
828	838	critically	critically	RB
839	848	regulates	regulate	VBZ
849	852	the	the	DT
853	866	CD40-mediated	cd40-mediated	JJ
867	882	differentiation	differentiation	NN
883	885	of	of	IN
886	906	non-antigen-selected	non-antigen-selected	JJ
907	912	human	human	JJ
913	914	B	b	NN
915	920	cells	cell	NNS
920	921	.	.	.